COPD | GenomeWeb

COPD

Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.

This Week in PLOS

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.

The company is developing a proteomic test for chronic obstructive pulmonary disease that it plans to launch in early 2018 as a CLIA-based diagnostic.

Data for tens of thousands of UK Biobank participants revealed an overlapping set of variants involved in airflow obstruction in heavy and never smokers. 

The technology uses infrared spectroscopy to indentify biomarkers of chronic obstructive pulmonary disease in sputum samples.

NEW YORK (GenomeWeb) – Glyconics, a UK firm using infrared spectroscopy to diagnose respiratory diseases, said today that it recently secured a contract from the Small Business Research Initiative for Healthcare to validate its technology.

NEW YORK (GenomeWeb News) – Two investigators at the University of British Columbia have received C$7.2 million (US$6.8 million) in funding to develop a biomarker-based blood test to identify patients with chronic obstructive pulmonary disorder who are most at risk for lung attacks.

Canada's Prevention of Organ Failure Centre of Excellence has granted HTG Molecular Diagnostics exclusive rights to commercialize a risk stratification test the center has been developing to better personalize treatment for chronic obstructive pulmonary disease.

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics said today that it has licensed exclusive rights from Vancouver's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) to commercialize gene expression tests for prognosis of COPD patients who will experience frequent lung a

Canada's Prevention of Organ Failure Centre of Excellence in Vancouver is using C$1.5 million (US$1.5 million) in funding from Genome British Columbia and other groups to develop a molecular test intended to personalize treatment for chronic obstructive pulmonary disease.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.